Enzon Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	43.26	46.86	47.01	46.98	47.64	48.14
Cash & Short-Term Investments	43.26	46.86	47.01	46.98	47.64	48.14
Cash Growth	-7.24%	-0.33%	0.06%	-1.38%	-1.04%	783.99%
Accounts Receivable	-	-	-	-	0.03	0.03
Receivables	-	-	-	-	0.03	0.03
Other Current Assets	0.41	0.29	0.33	0.41	0.09	0.06
Total Current Assets	43.67	47.15	47.34	47.39	47.75	48.23
Long-Term Deferred Tax Assets	0.03	0.02	0.36	0.2	-	-
Total Assets	43.69	47.17	47.7	47.59	47.75	48.23
Accounts Payable	0.33	0.33	0.33	0.33	0.33	0.3
Accrued Expenses	0.07	0.07	0.09	0.09	0.06	0.09
Other Current Liabilities	0.14	1.28	1.29	1.28	0.01	0.02
Total Current Liabilities	0.54	1.68	1.71	1.7	0.4	0.41
Total Liabilities	0.54	1.68	1.71	1.7	0.4	0.41
Common Stock	0.74	0.74	0.74	0.74	0.74	0.74
Additional Paid-In Capital	70.57	72.16	73.43	74.71	75.98	78.01
Retained Earnings	-72.23	-69.89	-70.67	-72.04	-71.86	-71.39
Total Common Equity	-0.92	3.01	3.51	3.41	4.87	7.36
Shareholders' Equity	43.15	45.49	45.99	45.89	47.35	47.82
Total Liabilities & Equity	43.69	47.17	47.7	47.59	47.75	48.23
Net Cash (Debt)	43.26	46.86	47.01	46.98	47.64	48.14
Net Cash Growth	-7.24%	-0.33%	0.06%	-1.38%	-1.04%	783.99%
Net Cash Per Share	0.58	0.63	0.63	0.63	0.64	0.94
Filing Date Shares Outstanding	74.21	74.21	74.21	74.21	74.21	74.21
Total Common Shares Outstanding	74.21	74.21	74.21	74.21	74.21	74.21
Working Capital	43.13	45.47	45.63	45.69	47.35	47.82
Book Value Per Share	-0.01	0.04	0.05	0.05	0.07	0.10
Tangible Book Value	-0.92	3.01	3.51	3.41	4.87	7.36
Tangible Book Value Per Share	-0.01	0.04	0.05	0.05	0.07	0.10

Source: S&P Global Market Intelligence. Standard template. Financial Sources.